Teva unlikely to succeed in bid for rehearing, Actavis tells US appeals court
MLex Summary: A stay of a New Jersey federal judge's injunction directing Teva to delist five patents from the US Food and Drug Administration's Orange Book of Approved Drugs should not...To view the full article, register now.
Already a subscriber? Click here to view full article